Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: An overview of celiac disease PART 06: Market landscape • Market overview • Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation by therapy type • First line of treatment • Second line of treatment PART 09: Geographical segmentation • Celiac disease drugs market in Americas • Celiac disease drugs market in EMEA • Celiac disease drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Inorganic growth strategies • Robust pipeline PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • F. Hoffmann-La Roche • Johnson & Johnson • Merck • Pfizer • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Stage 1: Initiation process in celiac disease Exhibit 02: Stage 2: Triggering phase in celiac disease Exhibit 03: Diagnostic approach for celiac disease Exhibit 04: Global celiac disease drugs market snapshot Exhibit 05: Global celiac disease drugs market 2016-2021 ($ millions) Exhibit 06: Opportunity analysis in global celiac disease treatment market Exhibit 07: Five forces analysis Exhibit 08: Pipeline analysis of key molecules for celiac disease Exhibit 09: Key clinical trials: Celiac disease drugs 2016 Exhibit 10: Segmentation of global celiac disease drugs market by therapy type 2016 Exhibit 11: Global celiac disease first line of treatment market 2016-2021 ($ millions) Exhibit 12: Various drug classes used in second line of treatment of celiac disease Exhibit 13: Global celiac disease second line of treatment market 2016-2021 ($ millions) Exhibit 14: Segmentation of global celiac disease drugs market by geography 2016 and 2021 Exhibit 15: Segmentation of global celiac disease drugs market revenue by geography 2016-2021 ($ millions) Exhibit 16: Market scenario in Americas Exhibit 17: Celiac disease drugs market in Americas 2016-2021 ($ millions) Exhibit 18: Market scenario in EMEA Exhibit 19: Celiac disease drugs market in EMEA 2016-2021 ($ millions) Exhibit 20: Market Scenario in APAC Exhibit 21: Celiac disease drugs market in APAC 2016-2021 ($ millions) Exhibit 22: Widely consumed foods containing gluten Exhibit 23: The consumption rate of beer in US 2011-2015 Exhibit 24: Government initiatives by various countries for celiac disease Exhibit 25: Various symptoms associated with celiac disease Exhibit 26: Factors affecting long-term sustainability of gluten-free diet Exhibit 27: Inorganic growth strategies for global celiac disease drugs market Exhibit 28: Competitive structure analysis of global celiac disease drugs market 2016 Exhibit 29: Competitive factors of global celiac disease drugs market Exhibit 30: Market penetration of various celiac disease drugs manufacturers worldwide 2016 Exhibit 31: Strategic success factors of companies in global celiac disease drugs market Exhibit 32: F. Hoffmann-La Roche: Key highlights Exhibit 33: F. Hoffmann-La Roche: Strength assessment Exhibit 34: F. Hoffmann-La Roche: Strategy assessment Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment Exhibit 36: Johnson & Johnson: Key highlights Exhibit 37: Johnson & Johnson: Strength assessment Exhibit 38: Johnson & Johnson: Strategy assessment Exhibit 39: Johnson & Johnson: Opportunity assessment Exhibit 40: Merck: Key highlights Exhibit 41: Merck: Strength assessment Exhibit 42: Merck Strategy assessment Exhibit 43: Merck: Opportunity assessment Exhibit 44: Pfizer: Key highlights Exhibit 45: Pfizer: Strength assessment Exhibit 46: Pfizer: Strategy assessment Exhibit 47: Pfizer: Opportunity assessment